Camoteskimab
Highest phase reached
Phase 2
Drug type
Antibody
- Listing at source
- Listed
- Highest phase reached
- Phase 2
- Drug type
- Antibody
- Drug name
- Camoteskimab
- aevi 007
- Aevi-007
- AEVI-007
- aevi007
- AEVI007
- avtx 007
- AVTX-007
- avtx007
- AVTX007
- camoteskimab
- Camoteskimab
- camoteskimab [INN]
- Camoteskimab [WHO-DD]
- camoteskimab inn
- camoteskimab who dd
- cerc 007
- CERC-007
- cerc007
- CERC007
- IMMUNOGLOBULIN G1 (242-PHENYLALANINE,243-GLUTAMIC ACID,339-SERINE), ANTI-(HUMAN INTERLEUKIN 18) (HUMAN MONOCLONAL CERC-007 .GAMMA.1-CHAIN), DISULFIDE WITH HUMAN MONOCLONAL CERC-007 .KAPPA.-CHAIN, DIMER
- immunoglobulin g1 242 phenylalanine 243 glutamic acid 339 serine anti human interleukin 18 human monoclonal cerc 007 gamma 1 chain disulfide with human monoclonal cerc 007 kappa chain dimer
- medi 2338
- MEDI-2338
- medi2338
- MEDI2338
- CAS registry numbers
- 2492472-82-7
- ChEMBL ID
- CHEMBL2109604
- FDA ingredient codes (UNII)
- ONX021SC9O
- Patents
- 0
- Designations
- 1
- First in class
- No
- Fast track
- No
- Breakthrough designation
- No
- Orphan designation
- No
- Priority review
- No
- Orphan exclusivity
- No
- Accelerated approval
- No
- Pharmacology name
- camoteskimab
- Type
- Antibody
- Drug name stem
- -mab
- Action
- Binding
- Action type
- Binding
- Target
- IL-18
- Gene symbol
- IL-18
- Mechanism
- Interleukin-18 cross-linking agent
- Action type
- CROSS_LINKING_AGENT
- Target
- Interleukin-18
- Protein identifier
- Q14116
Open Targets mechanisms
- Mechanism
- Interleukin-18 cross-linking agent
- Action type
- CROSS-LINKING AGENT
- Target
- Interleukin-18
- Condition
- Pulmonary Disease, Chronic Obstructive
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000341
- Subject identifier
- D029424
- Condition
- Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000616
- Subject identifier
- D009369
- Condition
- Multiple Myeloma
- Highest recorded phase
- 1
- Condition identifier
- EFO:0001378
- Subject identifier
- D009101
- Condition
- Still's Disease, Adult-Onset
- Highest recorded phase
- 1
- Condition identifier
- EFO:0007135
- Subject identifier
- D016706
- Condition identifier
- EFO_0000341
- Highest recorded phase
- 1
- Condition identifier
- EFO_0000616
- Condition identifier
- EFO_0001378
- Highest recorded phase
- 1
- Condition identifier
- EFO_0007135
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0004980
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005002
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005070
- Condition identifier
- MONDO_0009693
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0019355
- Highest recorded phase
- 1
- NCT01322594
- NCT04671251
- NCT04752371
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Natural product
- No
- Component
- Heavy chain
- Type
- Protein
- Sequence
- QVQLQESGPGLVKPSETLSLTCTVSGGSISADGYYWSWIRQPPGKGLEWIGSLYYSGSTYYNPSLKGRVTISGDTSKNQFSLKLSSVTAADTAVYYCARTPAYFGQDRTDFFDVWGRGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEFEGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPASIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
- Component
- Light chain
- Type
- Protein
- Sequence
- DIQMTQSPSTLSASVGDRVTITCRASQGISSWLAWYQQKPGKAPKVLIYKASTLESGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQSHHPPWTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
- Component
- Glycosylation sites (N)
- Sequence
- 305 $ 305''''
- Component
- Disulfide bridges
- Sequence
- 22-97 $ 22''-97'' $ 23'-88' $ 23'''-88''' $ 134'-194' $ 134'''-194''' $ 152-208 $ 152''-208'' $ 228-214' $ 228''-214''' $ 234-234'' $ 237-237'' $ 269-329 $ 269''-329'' $ 375-433 $ 375''-433''
- Component
- Glycosylation sites (N)
- Sequence
- 305 $ 305''
Related records
Trials (5)
- A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis
- A Study of the Effects of Camoteskimab in Adults With Moderate to Severe Atopic Dermatitis
- A Study to Evaluate Camoteskimab in Participants With Still's Disease
- A Study to Evaluate the Safety of MEDI2338 in Subjects With Chronic Obstructive Pulmonary Disease
- Phase 1b Study of AEVI-007 in Subjects With Relapsed or Refractory Multiple Myeloma
In development for (4)
- Adult-onset Still disease Phase 1
- Chronic obstructive pulmonary disease Phase 1
- Neoplasm Phase 2
- Plasma cell myeloma Phase 1
Targets (1)
- IL18 Interleukin-18 cross-linking agent